Children are affected by different forms of cancer than adults, there also exists a major difference between children and adults regarding treatment and development of new oncology therapies. The prominent variation is the concept of survival. With adult cancer patients, it is acceptable to look to immediate, 5 and 10-year survival rates, along with quality of life, for the best approximations of therapeutic success. On the other hand, a child cancer patient receives treatment to be cured. A typical difference between adult and pediatric oncologists is in treatment protocols; pediatric protocols are much more vigorous, often hitting patients “as hard as possible” to achieve a successful, long-term cure.
Paediatric Oncology Therapeutics Market: Drivers and Restraints
The market’s significant rise through the forecast period can be attributed to the industry as it is becoming more familiar with designing and implementing trials in the pediatric population. The growing incidence of disease conditions such as diabetes, hypertension and obesity in children is contributing to the surge of this segment. In addition, the recognition of chronic conditions such as diabetes and hypertension, along with certain behavioral health conditions such as Attention Deficit Hyperactivity Disorder (ADHD), depression and anxiety coupled with the rising prevalence of childhood obesity among the pediatric population is aiding the rise in these segments at a brisk rate.
However, the relatively small market of pediatric oncology does not provide the financial incentives for companies to actively pursue pediatric oncology solutions. In addition, the development of formulations for children a major challenge that separates pediatric drug development from mainstream R&D. Not surprisingly, each type of formulation poses difficulties depending on the age of the child which incurs additional cost for the companies.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2815
Paediatric Oncology Therapeutics Market: Segmentation
The paediatric oncology therapeutics market, is segmented on the basis of indication, treatment and region.
Segmentation by Indication
- Central Nervous System (CNS) disorders
- Bone Tumors
- Inflammatory disorders
- Respiratory disorders
Segmentation by Treatment
- Tumor Surgery
- Blood and Marrow Transplantation
- Drug Therapy
Segmentation by Region
- North America
Paediatric Oncology Therapeutics Market: Indication
Leukemias are the most common childhood cancers which are the cancers of the bone marrow and blood. Accounts for about 30% of all cancers in children. The most common types in children are Acute Myelogenous Leukemia (AML) and Acute Lymphocytic Leukemia (ALL).
Central Nervous System (CNS) and Brain tumors are the second most common cancers in children and account about 26% of childhood cancers. There are many types of brain tumors, and the treatment and outlook for each is different.
Cancers which that start in the bones (primary bone cancers) occur most often in older children and teens, however they can be developed at any age. They account for about 3% of childhood cancers. Two main types of primary bone cancers occur in children are Osteosarcoma and Ewing Sarcoma.
Retinoblastoma is a cancer of the eye. It accounts for about 2% of pediatric patients. It usually occurs in children around the age of 2, and is seldom found in children older than 6.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-2815
Paediatric Oncology Therapeutics Market: Treatment
Chemotherapy and radiotherapy are used as a first-line radical therapy in a number of paediatric oncology (such as ALL or AML) commonly used for palliation, where disease is clearly incurable. Often, surgery is attempted to remove a tumor entirely. This is only feasible when there is some degree of certainty that the tumor can in fact be removed.
A bone marrow transplant is a medical procedure in which bone marrow that contains cancer is replaced by hematopoietic stem cells that develop into healthy bone marrow.
There is also a rapid expansion in the use of monoclonal antibody treatments, notably for lymphoma (Rituximab), and breast cancer (Trastuzumab). Vaccine and other immunotherapies are the subject of intensive research and will take time to get added in the treatment for paediatric oncology.
Paediatric Oncology Therapeutics Market: Region
Geographically, the market is classified majorly into regions namely North America, Europe and Asia-Pacific.North America dominates the market due the presence of continuous sophisticated R&D technology development for paediatric oncology diagnosis and treatment in the region. Addition, the increasing incidence rate of cancer and obesity in children is contributing to the surge of this market augmenting for the market. APAC is expected to witness significant growth as compared to other regions and countries owing to increased healthcare and research expenditure.
Paediatric Oncology Therapeutics Market: Key Players
Some of the major hospitals which provides technologically advanced treatment for paediatric patients are St Jude Children’s Research Hospital (USA), St Louis Children’s Hospital (USA), Monroe Carell Jr. Children’s Hospital (USA), Birmingham Children’s Hospital (UK), Royal Children’s Hospital (Australia), National Center for Child Health and Development (Japan) and Dana-Dwek Children’s Hospital Tel Aviv Sourasky Medical Center (Israel).
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.